Article
Tumor mutational burden measurement using comprehensive genomic profiling assay.
Japanese journal of clinical oncology - 5 Aug 2022
Kage Hidenori, Kohsaka Shinji, Tatsuno Kenji, Ueno Toshihide, Ikegami Masachika, Zokumasu Koichi, Shinozaki-Ushiku Aya, Nagai Sumimasa, Aburatani Hiroyuki, Mano Hiroyuki, Oda Katsutoshi
Abstract excerpt
BACKGROUND: Tumors with a high number of mutations in the genome, or tumor mutational burden, are presumed to be more likely to respond to immune checkpoint inhibitors. However, the optimal method to calculate tumor mutational burden using comprehensive genomic profiling assays is unknown. METHODS: Todai OncoPanel is a dual panel of a deoxyribonucleic acid panel and a ribonucleic acid panel. Todai OncoPanel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.